| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Cassady JM et al. | Recent developments in the maytansinoid antitumor agents. | 2004 | Chem. Pharm. Bull. | pmid:14709862 |
| Liu Z et al. | An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. | 2004 | J Pharm Biomed Anal | pmid:15533675 |
| Henry MD et al. | A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. | 2004 | Cancer Res. | pmid:15520207 |
| Fleming MS et al. | A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. | 2005 | Anal. Biochem. | pmid:15840500 |
| Wang L et al. | Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. | 2005 | Protein Sci. | pmid:16081651 |
| Smith SV | Technology evaluation: huN901-DM1, ImmunoGen. | 2005 | Curr. Opin. Mol. Ther. | pmid:16121706 |
| Liu Z et al. | Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. | 2005 | J Mass Spectrom | pmid:15674857 |
| Lu SX et al. | Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. | 2005 | J Pharm Sci | pmid:15729708 |
| Lazar AC et al. | Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. | 2005 | Rapid Commun. Mass Spectrom. | pmid:15945030 |
| Frenzel T et al. | Synthesis of the N-acetylcysteamine thioester of seco-proansamitocin. | 2006 | Org. Lett. | pmid:16381586 |
| Kubota T et al. | Determination of the cryptic stereochemistry of the first PKS chain-extension step in ansamitocin biosynthesis by Actinosynnema pretiosum. | 2006 | Chembiochem | pmid:16927319 |
| Tijink BM et al. | A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. | 2006 | Clin. Cancer Res. | pmid:17062682 |
| Kovtun YV et al. | Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. | 2006 | Cancer Res. | pmid:16540673 |
| Floss HG | Combinatorial biosynthesis--potential and problems. | 2006 | J. Biotechnol. | pmid:16414140 |
| Erickson HK et al. | Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. | 2006 | Cancer Res. | pmid:16618769 |
| Widdison WC et al. | Semisynthetic maytansine analogues for the targeted treatment of cancer. | 2006 | J. Med. Chem. | pmid:16821799 |
| Wenzel SC et al. | On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of "glycolate" units into ansamitocin and soraphen A. | 2006 | J. Am. Chem. Soc. | pmid:17076505 |
| Snipes CE et al. | The ansacarbamitocins: polar ansamitocin derivatives. | 2007 | J. Nat. Prod. | pmid:17892263 |
| Goh S et al. | An integrative expression vector for Actinosynnema pretiosum. | 2007 | BMC Biotechnol. | pmid:17956638 |
| Sauter A et al. | Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. | 2007 | Int. J. Oncol. | pmid:17332932 |
| Meyer A et al. | Chemoenzymatic approaches toward dechloroansamitocin P-3. | 2007 | Org. Lett. | pmid:17378571 |
| Ma J et al. | New amide N-glycosides of ansamitocins identified from Actinosynnema pretiosum. | 2007 | Arch. Pharm. Res. | pmid:17679541 |
| Reddy JA et al. | Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. | 2007 | Cancer Res. | pmid:17616697 |
| Galsky MD et al. | Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. | 2008 | J. Clin. Oncol. | pmid:18362364 |
| Arai MA et al. | Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana. | 2008 | Bioorg. Med. Chem. | pmid:18842418 |
| Lewis Phillips GD et al. | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. | 2008 | Cancer Res. | pmid:19010901 |
| Riechelmann H et al. | Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. | 2008 | Oral Oncol. | pmid:18203652 |
| Chari RV | Targeted cancer therapy: conferring specificity to cytotoxic drugs. | 2008 | Acc. Chem. Res. | pmid:17705444 |
| Rodon J et al. | Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. | 2008 | Cancer Chemother. Pharmacol. | pmid:18301896 |
| Ishitsuka K et al. | Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. | 2008 | Br. J. Haematol. | pmid:18279455 |
| Taft F et al. | Highly active ansamitocin derivatives: mutasynthesis using an AHBA-blocked mutant. | 2008 | Chembiochem | pmid:18381586 |
| Ostermann E et al. | Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. | 2008 | Clin. Cancer Res. | pmid:18628473 |
| Stephan JP et al. | Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. | 2008 | Bioconjug. Chem. | pmid:18637680 |
| Zhao P et al. | Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins. | 2008 | Chem. Biol. | pmid:18721757 |
| Polson AG et al. | Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. | 2009 | Cancer Res. | pmid:19258515 |
| Taft F et al. | Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum. | 2009 | J. Am. Chem. Soc. | pmid:19292483 |
| Wang L et al. | Formal total synthesis of N-methylmaysenine. | 2009 | Org. Lett. | pmid:19296671 |
| Ikeda H et al. | The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. | 2009 | Clin. Cancer Res. | pmid:19509164 |
| Al-Katib AM et al. | Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. | 2009 | Clin. Cancer Res. | pmid:19509168 |
| Tang R et al. | P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. | 2009 | BMC Cancer | pmid:19549303 |
| Ng D et al. | Constitutive overexpression of asm2 and asm39 increases AP-3 production in the actinomycete Actinosynnema pretiosum. | 2009 | J. Ind. Microbiol. Biotechnol. | pmid:19609582 |
| Zheng B et al. | In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. | 2009 | Mol. Cancer Ther. | pmid:19808977 |
| Haeuw JF et al. | [Immunoconjugates, drug-armed antibodies to fight against cancer]. | 2009 | Med Sci (Paris) | pmid:20035677 |
| Lutz RJ and Whiteman KR | Antibody-maytansinoid conjugates for the treatment of myeloma. | 2009 Nov-Dec | MAbs | pmid:20068397 |
| Erickson HK et al. | Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. | 2010 | Bioconjug. Chem. | pmid:19891424 |
| Wang HH et al. | Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors. | 2010 | J. Alzheimers Dis. | pmid:20413892 |
| Yao Y et al. | Preparative isolation and purification of anti-tumor agent ansamitocin P-3 from fermentation broth of Actinosynnema pretiosum using high-performance counter-current chromatography. | 2010 | J Sep Sci | pmid:20235129 |
| Wei GZ et al. | A new antitumour ansamitocin from Actinosynnema pretiosum. | 2010 | Nat. Prod. Res. | pmid:20582809 |
| Kovtun YV et al. | Antibody-maytansinoid conjugates designed to bypass multidrug resistance. | 2010 | Cancer Res. | pmid:20197459 |
| Krop IE et al. | Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. | 2010 | J. Clin. Oncol. | pmid:20421541 |